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linicians making treatment decisions generally
refer to methodologically strong clinical trials examining
the impact of therapy on patient-important outcomes such
as morbid end points,ie,stroke,myocardial infarction,and
death,or health-related quality of life end points.These tri-
als require such a large sample size or long patient follow-
up that researchers have proposed the alternative of sub-
stituting surrogate outcomes or end points for the target
event,allowing shorter and smaller trials to be conducted.
This offers an apparently simpler solution to the difficulty
of conducting large or long-term trials.
A surrogate outcome can be defined as an outcome that
can be observed sooner,at lower cost,or less invasively
than the true outcome,and that enables valid inferences
about the effect of intervention on the true outcome.
Surrogate outcomes or end points (also known as surro-
gate markers) have to be distinguished from biomarkers,
although the two concepts are related.According to the
Biomarker Definitions Working Group,
1 a biomarker is
“a characteristic that is objectively measured and evalu-
ated as an indicator of normal biologic processes,patho-
genic process, or pharmacologic responses to a thera-
peutic intervention.” According to the US Food and
Drug Administration (FDA)
2 a “valid biomarker”is one
“that is measured in an analytical test system with well-
established performance characteristics and for which
there is an established framework or body of evidence
that elucidates the physiologic, toxicologic, pharmaco-
logic or clinical significance of the test result.”Thus,in the
drug development process, biomarkers can be useful
tools from the discovery stage, where they are used to
investigate pathophysiologic mechanisms related to
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A surrogate outcome can be defined as an outcome that
can be observed sooner, at lower cost, or less invasively
than the true outcome, and that enables valid inferences
about the effect of intervention on the true outcome.
There is increasing interest in the use of surrogate out-
comes of treatment efficacy measurement in investiga-
tional drug trials. However, the significance of surrogate
markers of treatment outcome in neurology and psychi-
atry has not yet been sufficiently demonstrated. Few
such markers have been adequately “validated,” that is,
shown to predict the effect of the treatment on the clin-
ical outcome of interest. In this article, evidence that
would support the validation of such markers is dis-
cussed. Biomarkers used during early clinical develop-
ment programs of new psychotropic compounds are con-
sidered in the contexts of Parkinson’s disease, affective
disorder, and schizophrenia. The particular case of neu-
roprotective trials is exemplified by Parkinson’s disease,
where a biomarker substituting for a clinical measure of
progression could be considered as a surrogate treat-
ment outcome.     
© 2006, LLS SAS Dialogues Clin Neurosci. 2006;8:345-352.either diagnosis or prognosis of a disease, through the
later stages of clinical development.Biomarkers can be
used in preclinical studies to confirm in vivo activity as
well as to investigate dose-response relationships.During
early clinical development programs (phase 1 and 2a),
biomarkers are used to evaluate activity and to develop
pharmacokinetic-pharmacodynamic relationships. In
phase 3 and 4 studies, biomarkers are useful tools for
stratifying study populations.
Surrogate outcomes are biomarkers that fit the following
definition:“a biomarker that is intended to substitute for
a clinical end point.A surrogate end point is expected to
predict clinical benefit (or harm or lack of benefit or harm)
based on epidemiologic,therapeutic,pathophysiologic,or
other scientific evidence.”
1This definition of a surrogate
outcome illustrates the key difference versus the role of
the biomarker.A biomarker can be used as a surrogate
outcome if it can reasonably predict a clinical benefit.Thus,
although a surrogate outcome is by definition a biomarker,
in fact,a very small minority of biomarkers meet the stan-
dard of a surrogate outcome. Before 1991, regulatory
agencies such as the FDA used surrogate treatment out-
comes in limited settings, mainly in the cardiovascular
area. For example, antihypertensive drugs have been
approved for marketing based on their effectiveness in
lowering blood pressure,and cholesterol-lowering agents
have been approved based on their ability to decrease
serum cholesterol, not on the direct evidence that they
decrease mortality from cardiovascular diseases.In 1991,
during the acquired immune deficiency syndrome (AIDS)
epidemic,surrogate outcomes were utilized for the first
time as a viable path toward regulatory approval.Indeed,
an important milestone was the use of CD4 cell count as
a surrogate marker,because of its predictive value for out-
come.This led to the approval of didanosine for the treat-
ment of HIV.In 1992,the FDA formulated a new regula-
tory process,often referred to as “accelerated approval,”
under which marketing approval can be provided for
interventions that have been shown to have compelling
effects on a validated surrogate treatment outcome.
At the present time,there are well-defined procedures in
the FDA in which such approvals are routinely exam-
ined
3;for example,some anticancer treatments have been
approved under the accelerated approval regulations.
3 In
these cases,drugs tested in patients refractory to avail-
able treatments are approved on the basis of their effects
on tumor size, as assessed by imaging. The labeling
adopted at the time of the approval indicates that the
approval was based on the effects of the treatment on
tumor size,without evidence of an effect on other clini-
cal variables.It is only when subsequent studies demon-
strate an effect on clinical outcome that the labeling is
changed to include a description of the documented
effect on survival.
In the field of drugs acting on the central nervous system
(CNS),no treatments for neurologic or psychiatric dis-
eases have been approved to date on the basis of an
effect on a surrogate outcome.One obvious reason for
this is the fact that no surrogate outcomes have been val-
idated until now;this will be discussed in the next section.
Surrogate outcome validation
The presence of a correlation does not suffice to justify
the replacement of a true clinical outcome by a surrogate
marker of this outcome. Indeed, a surrogate outcome
might not involve the same pathophysiologic process that
results in the true clinical outcome.In oncology,an ele-
vated level of a tumor marker such as prostate-specific
antigen (PSA) in prostate cancer is the indication of an
advanced tumor stage,and is clearly correlated with mor-
bidity/mortality risks.However,PSA is not the mecha-
nism through which the disease process influences the
clinical outcome.It is thus questionable whether treat-
ment-induced changes in this marker accurately predict
treatment-induced effects on the clinical end points.
4,5
General guidelines for the interpretation of clinical trials
using surrogate outcomes have been proposed.
6 In a
recent paper,Fleming
7 suggested a four-level hierarchy
for outcome measures.
Level 1 is a true clinical efficacy measure,and includes
those outcomes that directly reflect real benefits for the
patient;for example,reducing the risk of stroke could be
a surrogate for reducing the risk of death.
Level 2 is a validated surrogate outcome for a specific
disease setting and class of intervention.This outcome,
while not directly representing tangible clinical benefits,
can be used to reliably predict the level of such benefits.
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Selected abbreviations and acronyms
FDA Food and Drug Administration
fMRI functional magnetic resonance imaging
PET positron emission tomography
PSA prostate-specific antigen
REM rapid eye movement
SPECT single photon-emission computed tomographyAn example is blood pressure reduction as a surrogate
risk for stroke,for a well-studied class of antihyperten-
sive agents.
Level 3 is a nonvalidated surrogate outcome, yet one
established to be reasonably likely to predict clinical ben-
efit for a specific disease setting and class of intervention.
“Reasonably likely”implicates considerable clinical evi-
dence that the effect of the intervention on the surrogate
outcome measure (i) will accurately represent the effect
of the intervention on what is thought to be the pre-
dominant mechanism through which the disease process
induces tangible events; (ii) does not have important
adverse effects on the clinical efficacy end point that
would not be detected by the outcome measure;(iii) is
consistent with the effects on the true clinical outcome;
and (iv) is sufficiently strong and durable that it is rea-
sonably likely to product meaningful clinical benefits on
clinical efficacy measures.Illustrations of this level 3 of
outcome measures would be a reduction in viral load to
an undetectable level for 6 months in patients with
advanced HIV infection.
Level 4 is a correlate outcome that is a measure of bio-
logical activity,but that has not been established to be at
a higher level in this four-level hierarchy for outcome
measures;biological markers,such as PSA,that almost
certainly do not represent the biological mechanism
through which the disease process induces clinically tan-
gible events,would tend to be at level 4.
Marketing approval under the accelerated approval
process can be provided for interventions having com-
pelling effects on biological markers that are at least at
level 3 in the hierarchy.In the field of drugs acting on the
CNS, to date no compounds have been approved with
the accelerated approval procedure on the basis of an
effect on a surrogate outcome.This highlights the lack of
strongly validated (ie,level 1,2,or 3) surrogate outcomes
in the field of neurology and psychiatry.The following
sections will focus on definitions,applications,successes,
and failures of biomarkers in Parkinson’s disease,affec-
tive disorder,and schizophrenia,although similar exam-
ples could be found for many other neurological or psy-
chiatric disorders.
Neurology: Parkinson’s disease
Parkinson’s disease is a progressive neurodegenerative
disorder characterized by rigidity,bradykinesia,postural
instability,and tremor.Clinical decline reflects the ongo-
ing degeneration of dopaminergic neurons.Development
of specific biomarkers for Parkinson’s disease may be
useful at the onset of neurodegeneration,the onset of dis-
ease,and/or to mark disease progression.At present,the
most mature surrogate measures for Parkinson’s disease
are based on the functional imaging of dopaminergic
neurons with dopamine transporter ligands on the mea-
sures of dopamine metabolism with fluorodopa.
8,9 2-β-
Carbomethoxy-3-β-(4-[
125I]iodophenyl)tropane (
123I-b-
CIT),a single photon-emission computed tomography
(SPECT) radioligand that binds to the dopamine trans-
porter on the presynaptic dopamine terminal,
10 has been
most extensively evaluated as a potential surrogate out-
come in Parkinson’s disease.It has been reliably shown
to distinguish healthy control subjects from parkinsonian
patients.
11 Moreover, longitudinal studies reveal an
annual 6% to 10% reduction in striatal dopamine trans-
porter as measured by 
123I-b-CIT uptake in early
Parkinson’s disease, with a slower decline in more
advanced disease.
9,12 However,the results of CALM-PD
trial and the ELLDOPA trial contradicted these results.
In the CALM-PD trial,subjects with early Parkinson’s
disease requiring dopaminergic therapy were random-
ized to either initial pramipexole or initial levodopa.
13A
subgroup of patients (n=28) were studied in terms of rate
of striatal dopamine transporter loss as measured by
SPECT 
123I-b-CIT uptake.
14 Results show that,over the
course of 46 months, the pramipexole-treated patients
showed a 16% decline in striatal uptake compared with
25% in the levodopa group.The biomarker advantage of
pramipexole,however,did not translate into a clear,clin-
ically meaningful advantage.Indeed,although patients
on pramipexole had a lower incidence of complications,
patients randomized to initial levodopa had an early and
sustained improvement in function,and less somnolence
and edema.In the ELLDOPA trial
15 during which three
increasing doses of levodopa were compared with
placebo in patients with early Parkinson’s disease not
requiring dopaminergic therapy,discordant results were
noted between the clinical outcomes and the neu-
roimaging end point.Analysis of the 
123I-b-CIT outcome
suggested a trend toward a more rapid decline in striatal
dopamine transporter in individuals on the highest doses
of levodopa, but the largest clinical improvement was
observed in the levodopa group,in the direction oppo-
site to what would be predicted on the basis of the imag-
ing marker. These results corroborate those of the
CALM-PD trial,and indicate that the SPECT 
123I-b-CIT
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347biomarker advantage did not translate into a clinically
meaningful advantage.
Studies using 
18F6-fluoro-L-dopa (F-dopa) positron emis-
sion tomography (PET) as a surrogate outcome of
Parkinson’s disease treatment show similar negative
results.The accumulation of these radioactive dopamine
metabolites within the striatum,and evidence correlat-
ing their reduction with clinical and pathologic mea-
sures,
16-18 make F-dopa PET a potential surrogate out-
come for treatment assessment.In the REAL PET trial,
2 years after starting treatment,a 13% decline in F-dopa
uptake was seen in the ropinirole group compared with
a 20% decline in the levodopa group.
19 However,patients
treated with levodopa had significantly greater functional
improvement and fewer side effects (excepting dyskine-
sia),suggesting that F-dopa PET did not meet criteria for
a surrogate outcome of treatment efficacy.Additional
concerns regarding the ability to utilize PET as a marker
of therapeutic efficacy come from studies evaluating the
safety and efficacy of fetal tissue transplantation.
20-22 In
these studies,a significant increase in F-dopa uptake was
demonstrated in patients receiving fetal tissue trans-
plantation.Regrettably,functional improvement was not
clearly established,and a significant proportion of treated
subjects in both studies developed disabling dyskinesias.
This is a clear example of a case where unexpected con-
sequences of an intervention,not detected by a potential
surrogate outcome,resulted in patient harm.
The negative results of these trials have raised questions
regarding the use of biomarkers in Parkinson’s disease.
How can drugs affect a biomarker that suggests a slow-
ing of disease progression in the absence of symptomatic
benefits? How should symptomatic benefits in the
absence of disease-modifying effects be weighed against
modest neuroprotective effects in the absence of symp-
tomatic benefits? Are biomarkers any better than clini-
cal measures? 
Some of these questions are being addressed in neuro-
protective trials for Parkinson’s disease.The rationale for
these trials relies on the fact that in vitro and in vivo stud-
ies have established that there is abnormal oxidative
stress in Parkinson’s disease.
23-25 The link between this
particular disease mechanism and the clinical symptoms
of the illness,however,is weak,and the goal of the trial
is to detect no change in clinical status;even a worsening
in clinical status could be considered a success if the rate
of worsening is slower than expected.On the other hand,
an improvement in clinical status is considered as a
potential confounding factor since it may not relate to
the neuroprotective potency of the drug but,for instance,
to direct effects on the synaptic transmission.This is illus-
trated by the DATATOP study,
26 a trial designed with the
hypothesis that deprenyl, a monoamine oxidase B
inhibitor,the antioxidant α-tocopherol,and the combi-
nation of the two compounds,might slow the clinical pro-
gression of the disease.The results showed that patients
on deprenyl were found to be less likely to require
dopaminergic therapy over time,a finding that could be
interpreted as evidence of a neuroprotective effect in
cases of unaltered clinical status.However,the reason for
the difference was that deprenyl produced a small but
statistically significant symptomatic benefit, casting
doubts about its neuroprotective effect.
27Accordingly,the
DATATOP study demonstrates that,in trials assessing
the effects of a neuroprotective drug,clinical measures
cannot be considered as a gold standard for measuring
disease progression.In this particular case,a biomarker
directly reflecting disease progression could be substi-
tuted for a clinical measure of progression.
Psychiatry: affective disorder 
and schizophrenia
Clinical outcome measures in psychiatry provide several
challenges for drug developers.Periods of several weeks
or longer can be necessary to detect a response.Often,
assessments are obtained from rating scales,which are
based on psychometric,rather than pathophysiological,
principles.Moreover,placebo response rates are high for
many indications.Surrogate measures be applied to over-
come these difficulties,but research in this field is still in
its infancy.One may acknowledge that,compared with
some neurological diseases such as Parkinson’s disease,
illness-specific biomarkers are more poorly defined in
psychiatry.In this context,defining surrogate treatment
outcomes in psychiatry is premature to say the least.At
the present time,only a few biomarkers have been pro-
posed as surrogate outcomes for screening of new drugs
in early clinical phases. Accordingly, this discussion is
focused on biomarkers of potential interest.
Affective disorder 
Affective disorder is characterized by episodes of depres-
sion and in some cases, of mania, that recur and remit
repeatedly and cause shifts in a person's mood,energy,
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tive disorder, ie, bipolar disorder, patients experience
cycling of moods that usually swing from being overly
elated or irritable to sad and hopeless and then back
again, with periods of normal mood in between.
Unequivocally validated biomarkers for affective disor-
der are sparse;there are,however,studies suggesting that
measurement of stress hormone regulation processes,of
rapid eye movement (REM) sleep or of functional mag-
netic resonance imaging (fMRI) activation of limbic
areas could represent valuable surrogate outcome of
pharmacological antidepressant activity.Stress-related
dysfunctional neuroendocrine regulation implicating the
corticotropin-releasing hormone (CRH) system has been
consistently demonstrated in major depression,
28,29 and it
has been proposed that neurodocrine dynamic challenge
tests such as the combined dex/CRH test serve as a
screening tool to demonstrate the antidepressive effects
of new compounds in clinical drug trials.
30,31
Indices of REM sleep disinhibition, such as shortened
latency to REM sleep and increased density of ocular
movement during REM sleep,have been proposed as a
familial sleep biomarker for increased risk of developing
depression.
32 Indeed,many studies,recently reviewed,
33
suggest that REM sleep disinhibition could reflect a dys-
function of the monoaminergic system involved in the
pathophysiology of affective disorder.Drugs increasing
noradrenergic or serotoninergic functions inhibit REM
sleep,a property shared by most antidepressant drugs.
Consequently,REM sleep inhibition has been proposed
as a potential biomarker of the antidepressant activity of
a compound.
34,35
Dysfunction of the prefrontal cortex,including the ventral
anterior cingulate gyrus,has been implicated in anhedo-
nia, exaggerated response to stress, abnormal response
after presentation of mood-lowering stimuli,serotoniner-
gic challenges (such as tryptophan depletion paradigms),
or selective serotonin reuptake inhibitor (SSRI) admin-
istration (reviewed by Hassler et al
36).Changes in anterior
cingulate function during affective facial processing asso-
ciated with symptomatic improvement indicate that such
an fMRI activation paradigm may be a useful surrogate
outcome of antidepressant treatment response.
37Another
area of interest whose dysfunctional activation could serve
as a surrogate outcome of antidepressant activity is the
amygdala.Affective disorders have been characterized by
an increased basal metabolism of the amygdala
38 that
seems to relate to hypercortisolism and REM sleep abnor-
malities.
37 Increased amygdala reactivity in response to
fearful stimuli has been observed in healthy individuals
with a susceptibility to affective disorders.
39-41 Moreover,a
recent study in healthy volunteers showed that antide-
pressant administration decreases amygdala responses to
the presentation of fearful stimuli.
42This indicates that the
amygdala response to fearful stimuli,even in healthy sub-
jects,could represent a surrogate outcome of the pharma-
cological effects of antidepressants.
Schizophrenia 
Schizophrenia is a chronic psychiatric illness manifested
by characteristic and severe distortions of thinking and
perception, and by inappropriate or blunted affect.
Symptoms of schizophrenia may be divided into positive
symptoms (including hallucinations,delusions,and dis-
organized speech and behavior), negative symptoms
(including a decrease in emotional range, poverty of
speech,loss of interests,and loss of drive) and cognitive
symptoms (including deficits in attention and executive
functions such as organizational ability and abstract
thinking).The diagnosis is made from a pattern of signs
and symptoms, in conjunction with impaired occupa-
tional or social functioning. As for affective disorder,
there are,at the present time,no surrogate treatment out-
comes for schizophrenia. Some biomarkers have been
proposed as tools for the development of new antipsy-
chotic drugs,and will be further discussed.
Abnormal evoked response electronecephalography
(EEG) potentials have been shown to characterize
patients with schizophrenia,and are suggested to reflect
disturbances of neuropsychological functioning. In this
model,it is believed that schizophrenia patients are over-
whelmed by sensory input that they have trouble organiz-
ing,due to a deficit in the filtering or the gating process of
extraneous sensory stimuli.
43,44Among the several meth-
ods that have been used to investigate this putative deficit
in inhibitory neuronal processing,we will focus on the two
most widely used techniques,P50 auditory sensory gating
and the prepulse inhibition of the acoustic startle response.
Abnormal P50 and prepulse inhibition responses have
been observed in patients with schizophrenia and in their
families.
44,45The P50 is a small-amplitude,positive event-
related potential that occurs about 50 msec after an audi-
tory stimulus.Repeated pairs of clicks,separated by about
500 msec,typically elicit an initial excitatory response fol-
lowed by a diminished response,because the inhibitory
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the excitatory response to the second stimulus.The per-
centage reduction in the amplitude of the P50 response
from the first to the second click is the dependent variable
labeled “P50 suppression.”Significantly lower suppression
is found in schizophrenia patients.
44-47 Interestingly,treat-
ment with clozapine,but not with conventional antipsy-
chotic drugs such as haloperidol, reverses this deficit.
48
Moreover,subsequent studies have shown that other atyp-
ical antipsychotic medication did not share this property
with clozapine
49 and that improvement in P50 sensory gat-
ing was a predictor of clozapine response in schizophrenia
patients.
50These findings suggest that P50 could be a valu-
able biomarker for the development of new antipsychotic
agents,given the fact that clozapine is clinically more effec-
tive in a significant proportion of schizophrenic patients
refractory to other drug treatment.
Another auditory electrophysiological parameter assess-
ing sensorimotor gating is the prepulse inhibition of the
acoustic startle response.It refers to the ability of a weak
(prepulse) stimulus to transiently inhibit the reflex
response to a closely following stronger (pulse) stimulus.
Prepulse inhibition deficits have been observed in
patients with schizophrenia
44,45 including in drug-naïve
patients.
51,52 In rats,prepulse inhibition is disrupted by sys-
temic administration of dopamine agonists, serotonin
agonists,or glutamate antagonists,and this paradigm has
been proposed as an animal model for predicting
antipsychotic activity of novel compounds.
53As for P50
suppression, there is preliminary evidence suggesting
that,in contrast to other antipsychotic drugs including
atypical antipsychotics,clozapine treatment improves the
prepulse inhibition deficits of schizophrenic patients.
54
This indicates that indices of sensorimotor gating deficit
measured by either P50 or prepulse inhibition paradigms
are interesting biomarkers for the development of new
clozapine-like antipsychotic drugs.
Conclusions
At this time, the significance of surrogate markers of
treatment outcome in neurology and psychiatry is not
yet sufficiently understood; moreover, no surrogate
markers have been validated to be used as a sole pri-
mary measure of effectiveness in trials of investigational
drugs.Although unvalidated (in the sense described ear-
lier) surrogate outcomes have been successfully used
for anticancer or anti-AIDS drugs, a sponsor who
wishes to obtain approval on the basis of the effect of a
drug on such an unvalidated marker will need to ade-
quately demonstrate that any such effect will be “rea-
sonably likely” to predict the desired clinical effect.
Evidence supporting this remains to be found. It may
include both animal and human data,and requires fur-
ther investigation into the pathophysiology of the con-
dition under study and into the pharmacology of the
drug under study. ❏
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Mediciones sustitutas en neurología, 
psiquiatría y psicofarmacología
Una medición sustituta se puede definir como un
parámetro (marcador) mensurable en forma pre-
coz, a un menor costo y de manera menos invasora
que el parámetro real; y que permite inferencias
válidas acerca del efecto de la intervención en el
parámetro real. Existe un creciente interés en el
empleo de mediciones sustitutas de la eficacia tera-
péutica en investigación de ensayos de fármacos.
Sin embargo, el significado de mediciones sustitu-
tas de eficacia terapéutica en neurología y psiquia-
tría aun no ha sido suficientemente demostrado.
De hecho, pocos de estos marcadores han sido ade-
cuadamente “validados,” es decir, que hayan mos-
trado su valor predictor en relación al  efecto clínico
de un determinado tratamiento. En este artículo se
discute la evidencia que podría sustentar la valida-
ción de tales marcadores. Los biomarcadores emple-
ados durante los programas de desarrollo iniciales
de nuevos fármacos psicotrópicos son considerados
en el contexto de la enfermedad de Parkinson, los
trastornos afectivos y la esquizofrenia. El caso par-
ticular de los ensayos de moléculas neuroprotecto-
ras está ejemplificado en la enfermedad de
Parkinson, donde un biomarcador sustituto para la
medición clínica de la progresión de la enfermedad
podría considerarse como una medición sustituta
de la eficacia del tratamiento. 
Marqueurs de substitution en neurologie,
psychiatrie et psychopharmacologie
Un marqueur de substitution peut se définir comme
un paramètre (marqueur) mesurable de façon plus
précoce, ou moins invasive, ou encore pour un coût
moindre que le paramètre réel, et qui permet de
tirer des conclusions valides sur l’effet d’une théra-
peutique sur ce paramètre réel. Un intérêt croissant
se porte sur l’utilisation de tels marqueurs de subs-
titution dans le domaine des études d’évaluation
clinique des médicaments. Toutefois, la pertinence
des marqueurs de substitution d’efficacité n’a pas
encore été démontrée de façon satisfaisante dans
les domaines de la neurologie et de la psychiatrie.
En effet, peu parmi ces marqueurs ont été suffi-
samment « validés », c’est-à-dire, ont fait la preuve
de leur valeur prédictive quant à l’effet clinique
recherché du traitement. Cet article passe en revue
les arguments en faveur de la validation de ce type
de marqueur. Les biomarqueurs utilisés dans les
programmes de développement initiaux de nouve-
lles molécules psychotropes sont évoqués dans le
contexte de la maladie de Parkinson, des troubles
affectifs et de la schizophrénie. Le cas particulier
des essais cliniques de molécules à visée neuropro-
tectrice est illustré par la maladie de Parkinson, où
un biomarqueur de la progression de la maladie
pourrait être considéré comme marqueur de subs-
titution du résultat thérapeutique.
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